These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Vaginal deployment and tenofovir delivery by microbicide gels. Gao Y; Yuan A; Chuchuen O; Ham A; Yang KH; Katz DF Drug Deliv Transl Res; 2015 Jun; 5(3):279-94. PubMed ID: 25874971 [TBL] [Abstract][Full Text] [Related]
4. MTN-001: randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments. Hendrix CW; Chen BA; Guddera V; Hoesley C; Justman J; Nakabiito C; Salata R; Soto-Torres L; Patterson K; Minnis AM; Gandham S; Gomez K; Richardson BA; Bumpus NN PLoS One; 2013; 8(1):e55013. PubMed ID: 23383037 [TBL] [Abstract][Full Text] [Related]
5. AIDS: Drugs that prevent HIV infection. Wainberg MA Nature; 2011 Jan; 469(7330):306-7. PubMed ID: 21248832 [No Abstract] [Full Text] [Related]
6. Clinical development of microbicides for the prevention of HIV infection. D'Cruz OJ; Uckun FM Curr Pharm Des; 2004; 10(3):315-36. PubMed ID: 14754390 [TBL] [Abstract][Full Text] [Related]
7. RMP-02/MTN-006: A phase 1 rectal safety, acceptability, pharmacokinetic, and pharmacodynamic study of tenofovir 1% gel compared with oral tenofovir disoproxil fumarate. Anton PA; Cranston RD; Kashuba A; Hendrix CW; Bumpus NN; Richardson-Harman N; Elliott J; Janocko L; Khanukhova E; Dennis R; Cumberland WG; Ju C; Carballo-Diéguez A; Mauck C; McGowan I AIDS Res Hum Retroviruses; 2012 Nov; 28(11):1412-21. PubMed ID: 22943559 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and topical vaginal effects of two tenofovir gels in rabbits. Clark MR; Friend DR AIDS Res Hum Retroviruses; 2012 Nov; 28(11):1458-66. PubMed ID: 22394281 [TBL] [Abstract][Full Text] [Related]
10. FAME-04: A Phase 1 trial to assess the safety, acceptability, pharmacokinetics and pharmacodynamics of film and gel formulations of tenofovir. Bunge KE; Dezzutti CS; Hendrix CW; Marzinke MA; Spiegel HML; Moncla BJ; Schwartz JL; Meyn LA; Richardson-Harman N; Rohan LC; Hillier SL J Int AIDS Soc; 2018 Aug; 21(8):e25156. PubMed ID: 30101439 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and Pharmacodynamics of Tenofovir Reduced-Glycerin 1% Gel in the Rectal and Vaginal Compartments in Women: A Cross-Compartmental Study With Directly Observed Dosing. Justman JE; Nair GL; Hendrix CW; Piper JM; Marzinke MA; Dai JY; Pan Z; Galaska B; Levy L; Schwartz JL; Balar B; Kunjara Na Ayudhya RP; Mushamiri I; McGowan I; Dezzutti CS; J Acquir Immune Defic Syndr; 2018 Jun; 78(2):175-182. PubMed ID: 29767639 [TBL] [Abstract][Full Text] [Related]
12. Durable protection from vaginal simian-human immunodeficiency virus infection in macaques by tenofovir gel and its relationship to drug levels in tissue. Dobard C; Sharma S; Martin A; Pau CP; Holder A; Kuklenyik Z; Lipscomb J; Hanson DL; Smith J; Novembre FJ; García-Lerma JG; Heneine W J Virol; 2012 Jan; 86(2):718-25. PubMed ID: 22072766 [TBL] [Abstract][Full Text] [Related]
13. Acceptability of tenofovir gel as a vaginal microbicide among women in a phase I trial: a mixed-methods study. Rosen RK; Morrow KM; Carballo-Diéguez A; Mantell JE; Hoffman S; Gai F; Maslankowski L; El-Sadr WM; Mayer KH J Womens Health (Larchmt); 2008 Apr; 17(3):383-92. PubMed ID: 18328009 [TBL] [Abstract][Full Text] [Related]
14. Reformulated tenofovir gel for use as a dual compartment microbicide. Dezzutti CS; Rohan LC; Wang L; Uranker K; Shetler C; Cost M; Lynam JD; Friend D J Antimicrob Chemother; 2012 Sep; 67(9):2139-42. PubMed ID: 22581908 [TBL] [Abstract][Full Text] [Related]
15. A drug evaluation of 1% tenofovir gel and tenofovir disoproxil fumarate tablets for the prevention of HIV infection. Gengiah TN; Baxter C; Mansoor LE; Kharsany AB; Abdool Karim SS Expert Opin Investig Drugs; 2012 May; 21(5):695-715. PubMed ID: 22394224 [TBL] [Abstract][Full Text] [Related]
16. No evidence for selection of HIV-1 with enhanced gag-protease or Nef function among breakthrough infections in the CAPRISA 004 tenofovir microbicide trial. Chopera DR; Mann JK; Mwimanzi P; Omarjee S; Kuang XT; Ndabambi N; Goodier S; Martin E; Naranbhai V; Karim SA; Karim QA; Brumme ZL; Ndung'u T; Williamson C; Brockman MA; PLoS One; 2013; 8(8):e71758. PubMed ID: 24015191 [TBL] [Abstract][Full Text] [Related]
17. The sheep as a model of preclinical safety and pharmacokinetic evaluations of candidate microbicides. Holt JD; Cameron D; Dias N; Holding J; Muntendam A; Oostebring F; Dreier P; Rohan L; Nuttall J Antimicrob Agents Chemother; 2015 Jul; 59(7):3761-70. PubMed ID: 25845860 [TBL] [Abstract][Full Text] [Related]
18. Preservation HIV-1-specific IFNγ+ CD4+ T-cell responses in breakthrough infections after exposure to tenofovir gel in the CAPRISA 004 microbicide trial. Mureithi MW; Poole D; Naranbhai V; Reddy S; Mkhwanazi NP; Sibeko S; Werner L; Abdool Karim Q; Abdool Karim S; Ndung'u T; Altfeld M; J Acquir Immune Defic Syndr; 2012 Jun; 60(2):124-7. PubMed ID: 22362152 [TBL] [Abstract][Full Text] [Related]
19. Comparison of Dapivirine Vaginal Gel and Film Formulation Pharmacokinetics and Pharmacodynamics (FAME 02B). Robinson JA; Marzinke MA; Bakshi RP; Fuchs EJ; Radebaugh CL; Aung W; Spiegel HM; Coleman JS; Rohan LC; Hendrix CW AIDS Res Hum Retroviruses; 2017 Apr; 33(4):339-346. PubMed ID: 27809557 [TBL] [Abstract][Full Text] [Related]
20. Microbicides for HIV prevention. Ramjee G Indian J Med Res; 2011 Dec; 134(6):930-8. PubMed ID: 22310825 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]